Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients

References

• Borchmann P, Engert A. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010;2010: 101–107.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease:results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996;78:1293–1299.
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221–230.
   PubMed Web of Science ®Google Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin lymphoma responding to prior salvage therapy. Haematologica 2012;97:1073–1079.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980–5987.
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009;145:369–372.
   PubMed Web of Science ®Google Scholar
• Mocikova H, Pytlik R, Markova J, et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011;52:1668–1674.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665–1670.
   PubMed Web of Science ®Google Scholar
• Horning S, Fanale M, DeVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics:An international effort. Ann Oncol 2008;19(Suppl. 4): Abstract 118.
   Web of Science ®Google Scholar
• Currin ES, Gopal AK. Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol 2012;47:8–16.
   PubMedGoogle Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119–5125.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197–2203.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 2011; 48(Suppl. 1):S24–S36.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114(Suppl. 1): Abstract 405.
   Web of Science ®Google Scholar
• Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290–2292.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998;9(Suppl. 5):S103–S108.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PAJr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:468–480.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615–2619.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.
   PubMed Web of Science ®Google Scholar
• Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3–13.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012;119:692–695.
   PubMed Web of Science ®Google Scholar